<DOC>
	<DOCNO>NCT03035006</DOCNO>
	<brief_summary>This phase I/II dose-escalation study lipotecan base concurrent chemoradiotherapy hepatocellular carcinoma portal vein tumor thrombosis .</brief_summary>
	<brief_title>Lipotecan Based Concurrent Chemoradiotherapy Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis</brief_title>
	<detailed_description>Protocol number : TLCTLC388A1008 Primary objective : To evaluate safety tolerability , include maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) , Lipotecan base concurrent chemoradiotherapy ( CCRT ) patient hepatocellular carcinoma ( HCC ) portal vein tumor thrombosis ( PVTT ) unsuitable local treatment . Secondary Objective : The secondary objective explore efficacy Lipotecan base CCRT patient HCC PVTT effect quality life .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>1 . Patients male female ≥20 year age Taiwan ≥18 year old China 2 . Patients histologically confirm HCC patient histological diagnosis , lesion large 1 cm cirrhotic liver typical HCC image contrast enhance CT scan MRI . If image characteristic typical HCC , another contrast enhance image modality confirm diagnosis . 3 . Patients PVTT ( BCLC stage C ) suitable local therapy 4 . Patients measureable target lesion 5 . Patients anticipate residual life expectancy ≥3 month 6 . Patients adequate organ function 7 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 8 . Patients willing follow birth control requirement study treatment continue 2 month completion study treatment 9 . Patients willing able comply study procedure sign write ICF 1 . Patients infiltrative type HCC 2 . Patients evidence extrahepatic metastasis , include limited inferior vena cava thrombosis , bone metastasis , brain metastasis , regional lymph node metastasis 3 . Patients history West Haven criterion grade IIIIV hepatic encephalopathy ascites 4 . Patients history malignancy except primary HCC within 3 year prior screen visit , exclude skin squamous cell carcinoma basal cell carcinoma 5 . Patients fail follow radiation dose constraint critical organ radiotherapy plan 6 . Patients inadequately define hepatic tumor margin RT planning MRI CT may impact treatment safety base investigator 's judgment 7 . Patients experience significant allergy hypersensitivity contrast medium CT MRI make unsafe perform delineation RT planning 8 . Patients history liver transplantation 9 . Patients significant concurrent disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Portal vein tumor thrombosis</keyword>
	<keyword>TLC388</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Lipotecan</keyword>
</DOC>